<div id="readability-page-1"><p>Shares of Pfizer Inc. (NYSE:PFE - Get Free Report) have been assigned a consensus rating of &#34;Moderate Buy&#34; from the seventeen ratings firms that are currently  covering the stock, MarketBeat reports. One analyst  has rated the stock with a sell rating, eight have issued  a hold rating, five have issued  a buy rating and three have issued  a strong buy rating on  the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $31.07.</p><ul><li>2 Healthcare Stocks to Watch as JPMorgan Boosts Gilead Rating</li></ul><p>Several analysts have issued reports on the stock. Citigroup  reaffirmed a &#34;neutral&#34; rating on shares of Pfizer in a research report on Thursday, March 27th. Hsbc Global Res upgraded shares of Pfizer to a &#34;strong-buy&#34; rating in a research note on Monday, March 10th. Truist Financial reduced their price target on Pfizer from $36.00 to $32.00 and set a &#34;buy&#34; rating for the company in a report on Wednesday, December 18th. Guggenheim  reaffirmed a &#34;buy&#34; rating on shares of Pfizer in a research report on Tuesday, March 18th. Finally, The Goldman Sachs Group  reissued a &#34;neutral&#34; rating and set a $25.00 target price (down from $32.00) on shares of Pfizer in a report on Tuesday, April 8th.</p><p><b>Read Our Latest Analysis on PFE</b></p><h2>Pfizer Trading Up 1.4 %</h2><ul><li>Viking Therapeutics: Could GLP-1 Maker Be Acquired Pre-Approval?</li></ul><p>Shares of NYSE:PFE opened at $21.89 on Friday. The stock has a market capitalization of $124.14 billion, a PE ratio of 15.52, a price-to-earnings-growth ratio of 0.64 and a beta of 0.67. The company's 50-day moving average price is $25.25 and its two-hundred day moving average price is $26.40. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. Pfizer has a one year low of $20.92 and a one year high of $31.54. </p><p>Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, beating analysts' consensus estimates of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm had revenue of $17.76 billion during the quarter, compared to the consensus estimate of $17.26 billion. During the same period last year, the company earned $0.10 earnings per share. The business's revenue was up 24.7% compared to the same quarter last year.  On average, equities analysts forecast that  Pfizer will post 2.95 EPS for the current fiscal year. </p><h2>Insider Buying and Selling</h2><ul><li>These Stocks Missed on Earnings, But Will Rebound Next Quarter  </li></ul><p>In related news, Director Ronald E. Blaylock bought 19,457 shares of the company's stock in a transaction dated Thursday, February 13th. The stock was purchased at an average price of $25.65 per share, with a total value of $499,072.05. Following the completion of the acquisition, the director now owns 27,707 shares of the company's stock, valued at $710,684.55. The trade was a 235.84 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities &amp; Exchange Commission, which is available through the SEC website. 0.06% of the stock is currently owned by company insiders. </p><h2>Hedge Funds Weigh In On Pfizer</h2><p>Several large investors have recently bought and sold shares of the company. Retirement Wealth Solutions LLC acquired a new position in shares of  Pfizer in the fourth quarter worth approximately $26,000.  Rialto Wealth Management LLC bought a new stake in shares of  Pfizer in the 4th quarter valued at $26,000.  Clarity Asset Management Inc. acquired a new stake in shares of  Pfizer during the fourth quarter worth $27,000.  Gould Capital LLC raised its stake in  Pfizer by 97.2% during the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock worth $27,000 after buying an additional 493 shares during the last quarter.  Finally, Kohmann Bosshard Financial Services LLC acquired a new position in  Pfizer in the fourth quarter valued at $28,000. 68.36% of the stock is currently owned by institutional investors. </p><h2>Pfizer Company Profile</h2> (Get Free Report<p>Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.</p><h2>Read More</h2><ul><li>Five stocks we like better than Pfizer</li><li>Growth Investing: Should You Adopt This Investing Strategy in 2022?</li><li>Robinhood Strategies Could Be a Game-Changer for Young Investors</li><li>What is a Death Cross in Stocks?</li><li>Are These 3 Retail Stocks Oversold or Really in Trouble?</li><li>Investing in Travel Stocks Benefits</li><li>IONQ &amp; RGTI Join DARPA Quantum Initiative: High Stakes Are Ahead</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBGRQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="600" height="385" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBGRQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Pfizer Right Now?</h2><p>Before you consider Pfizer, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.</p><p>While Pfizer currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Pfizer Inc. (NYSE:PFE) has received a consensus rating of "Moderate Buy" from 17 brokerages. Ratings include one sell, eight hold, five buy, and three strong buy. The average 12-month target price is $31.07. Recent reports show Citigroup maintains a "neutral" rating, while HSBC upgraded to "strong buy." Pfizer's stock opened at $21.89, with a market cap of $124.14 billion. The company reported $0.63 EPS, exceeding estimates, with revenue of $17.76 billion, up 24.7% year-over-year. Insider buying was noted, with 68.36% of shares held by institutional investors.</p>

- Pfizer Inc. (NYSE:PFE) has a consensus rating of "Moderate Buy" from seventeen analysts, with one sell, eight hold, five buy, and three strong buy ratings.  
- The average 12-month target price is $31.07, while the stock opened at $21.89, with a market cap of $124.14 billion and a PE ratio of 15.52.  
- Pfizer reported $0.63 earnings per share for the last quarter, exceeding estimates, with revenue of $17.76 billion, a 24.7% increase from the previous year.  

Pfizer Inc. (NYSE:PFE) Given Consensus Recommendation of "Moderate Buy" by Brokerages